{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T16:30:37Z","timestamp":1787243437439,"version":"build-2736575974"},"reference-count":52,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000026","name":"NIDA","doi-asserted-by":"publisher","award":["R01DA039169"],"award-info":[{"award-number":["R01DA039169"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacology Biochemistry and Behavior"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1016\/j.pbb.2022.173482","type":"journal-article","created":{"date-parts":[[2022,10,13]],"date-time":"2022-10-13T05:00:06Z","timestamp":1665637206000},"page":"173482","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Gabapentin increases the abuse liability of alcohol alone and in combination with oxycodone in participants with co-occurring opioid and alcohol use disorder"],"prefix":"10.1016","volume":"221","author":[{"given":"F.","family":"Castillo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.D.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.R.","family":"Luba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Mogali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.W.","family":"Foltin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.M.","family":"Evans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.D.","family":"Comer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pbb.2022.173482_bb0005","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1007\/s002130100839","article-title":"Effect of gabapentin-like compounds on development and maintenance of morphine-induced conditioned place preference","volume":"157","author":"Andrews","year":"2001","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.pbb.2022.173482_bb0010","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1001\/jamainternmed.2020.0249","article-title":"Efficacy of gabapentin for the treatment of alcohol use disorder in patients with alcohol withdrawal symptoms: a randomized clinical trial","volume":"180","author":"Anton","year":"2020","journal-title":"JAMA Intern. Med."},{"key":"10.1016\/j.pbb.2022.173482_bb0015","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.drugalcdep.2005.10.008","article-title":"The acute effects of gabapentin in combination with alcohol in heavy drinkers","volume":"83","author":"Bisaga","year":"2006","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.pbb.2022.173482_bb0020","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/s002130050956","article-title":"Comparison of intravenous and intranasal heroin self-administration by morphine-maintained humans","volume":"143","author":"Comer","year":"1999","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.pbb.2022.173482_bb0025","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.drugalcdep.2009.12.018","article-title":"Abuse liability of oxycodone as a function of pain and drug use history","volume":"109","author":"Comer","year":"2010","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.pbb.2022.173482_bb0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2022.109400","article-title":"Nonmedical use of gabapentin and opioid agonist medications in treatment-seeking individuals with opioid use disorder","volume":"234","author":"Ellis","year":"2022","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.pbb.2022.173482_bb0035","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.drugalcdep.2010.09.001","article-title":"Response to alcohol in women: role of the menstrual cycle and a family history of alcoholism","volume":"114","author":"Evans","year":"2011","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.pbb.2022.173482_bb0040","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1037\/pha0000419","article-title":"Impulsivity and the effects of alcohol in women with a history of childhood sexual abuse: a pilot study","volume":"29","author":"Evans","year":"2021","journal-title":"Exp. Clin. Psychopharmacol."},{"key":"10.1016\/j.pbb.2022.173482_bb0045","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1111\/acer.13917","article-title":"Gabapentin enacarbil extended-release for alcohol use disorder: a randomized, double-blind, placebo-controlled, multisite trial assessing efficacy and safety","volume":"43","author":"Falk","year":"2019","journal-title":"Alcohol. Clin. Exp. Res."},{"key":"10.1016\/j.pbb.2022.173482_bb0050","first-page":"397","article-title":"Reliability and validity of SAFTEE: preliminar analyses","volume":"22","author":"Guy","year":"1986","journal-title":"Psychopharmacol. Bull."},{"key":"10.1016\/j.pbb.2022.173482_bb0055","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1007\/s40264-020-00985-6","article-title":"Current evidence on abuse and misuse of gabapentinoids","volume":"43","author":"H\u00e4gg","year":"2020","journal-title":"Drug Saf."},{"key":"10.1016\/j.pbb.2022.173482_bb0060","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.jsat.2019.11.008","article-title":"Prevalence of documented alcohol and opioid use disorder diagnoses and treatments in a regional primary care practice-based research network","volume":"110","author":"Hallgren","year":"2020","journal-title":"J. Subst. Abus. Treat."},{"key":"10.1016\/j.pbb.2022.173482_bb0065","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.drugalcdep.2006.05.028","article-title":"Smoked cocaine self-administration by humans is not reduced by large gabapentin maintenance doses","volume":"86","author":"Hart","year":"2007","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.pbb.2022.173482_bb0070","first-page":"1","article-title":"Drug overdose deaths in the United States, 1999\u20132019","author":"Hedegaard","year":"2020","journal-title":"NCHS Data Brief"},{"key":"10.1016\/j.pbb.2022.173482_bb0075","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1046\/j.1440-1819.2003.01161.x","article-title":"An open pilot study of gabapentin vs. Trazodone to treat insomnia in alcoholic outpatients","volume":"57","author":"Karam-Hage","year":"2003","journal-title":"Psychiatry Clin. Neurosci."},{"issue":"2","key":"10.1016\/j.pbb.2022.173482_bb1015","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s00213-013-3147-0","article-title":"In the company of others: social factors alter acute alcohol effects","volume":"230","author":"Kirkpatrick","year":"2013","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.pbb.2022.173482_bb0080","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1002\/phar.2309","article-title":"High-dose gabapentin for the treatment of severe alcohol withdrawal syndrome: a retrospective cohort analysis","volume":"39","author":"Levine","year":"2019","journal-title":"Pharmacother. J. Hum. Pharmacol. Drug Ther."},{"key":"10.1016\/j.pbb.2022.173482_bb0085","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1097\/FBP.0000000000000187","article-title":"Separate and combined effects of gabapentin and [INCREMENT]9-tetrahydrocannabinol in humans discriminating [INCREMENT]9-tetrahydrocannabinol","volume":"27","author":"Lile","year":"2016","journal-title":"Behav. Pharmacol."},{"key":"10.1016\/j.pbb.2022.173482_bb0090","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1146\/annurev-neuro-070815-013920","article-title":"The emergence of a circuit model for addiction","volume":"39","author":"L\u00fcscher","year":"2016","journal-title":"Annu. Rev. Neurosci."},{"key":"10.1016\/j.pbb.2022.173482_bb0095","doi-asserted-by":"crossref","first-page":"s16","DOI":"10.1080\/10550490190942489","article-title":"Update on anticonvulsants for the treatment of alcohol withdrawal","volume":"10","author":"Malcolm","year":"2001","journal-title":"Am. J. Addict."},{"key":"10.1016\/j.pbb.2022.173482_bb0100","first-page":"24","article-title":"Self-reported sleep, sleepiness, and repeated alcohol withdrawals: a randomized, double blind, controlled comparison of lorazepam vs gabapentin. J. Clin. Sleep med. JCSM off","volume":"3","author":"Malcolm","year":"2007","journal-title":"Publ. Am. Acad. Sleep Med."},{"key":"10.1016\/j.pbb.2022.173482_bb0105","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/S0022-3565(25)26119-5","article-title":"A comparative study of physiological and subjective effects of heroin and morphine administered intravenously in postaddicts","volume":"133","author":"Martin","year":"1961","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.pbb.2022.173482_bb0110","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1111\/j.1369-1600.2008.00133.x","article-title":"Proof-of-concept human laboratory study for protracted abstinence in alcohol dependence: effects of gabapentin","volume":"14","author":"Mason","year":"2009","journal-title":"Addict. Biol."},{"key":"10.1016\/j.pbb.2022.173482_bb0115","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1001\/jamainternmed.2013.11950","article-title":"Gabapentin treatment for alcohol dependence: a randomized controlled trial","volume":"174","author":"Mason","year":"2014","journal-title":"JAMA Intern. Med."},{"issue":"4","key":"10.1016\/j.pbb.2022.173482_bb5000","doi-asserted-by":"crossref","first-page":"529","DOI":"10.15288\/jsa.2006.67.529","article-title":"Simultaneous and concurrent polydrug use of alcohol and prescription drugs: prevalence, correlates, and consequences","volume":"67","author":"McCabe","year":"2006","journal-title":"J. Stud. Alcohol"},{"key":"10.1016\/j.pbb.2022.173482_bb0120","series-title":"Trends in Hospital Inpatient Stays in the United States","first-page":"18","volume":"2005\u20132014","author":"McDermott","year":"2017"},{"key":"10.1016\/j.pbb.2022.173482_bb0125","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2021.108886","article-title":"An examination between treatment type and treatment retention in persons with opioid and co-occurring alcohol use disorders","volume":"226","author":"Mintz","year":"2021","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.pbb.2022.173482_bb0130","doi-asserted-by":"crossref","DOI":"10.1186\/s13722-016-0065-6","article-title":"Alcohol use in opioid agonist treatment","volume":"11","author":"Nolan","year":"2016","journal-title":"Addict. Sci. Clin. Pract."},{"key":"10.1016\/j.pbb.2022.173482_bb0135","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1002\/phar.2096","article-title":"Predictors of gabapentin overuse with or without concomitant opioids in a commercially insured U.S. Population","volume":"38","author":"Peckham","year":"2018","journal-title":"Pharmacother. J. Hum. Pharmacol. Drug Ther."},{"key":"10.1016\/j.pbb.2022.173482_bb0140","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.0242","article-title":"Assessment of annual cost of substance use disorder in US hospitals","volume":"4","author":"Peterson","year":"2021","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.pbb.2022.173482_bb0145","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1176\/ajp.155.7.992","article-title":"Gabapentin as a potential treatment for anxiety disorders","volume":"155","author":"Pollack","year":"1998","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.pbb.2022.173482_bb0150","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1176\/appi.ajp.2021.20121757","article-title":"Effects of gabapentin on dorsal anterior cingulate cortex GABA and glutamate levels and their associations with abstinence in alcohol use disorder: a randomized clinical trial","volume":"178","author":"Prisciandaro","year":"2021","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.pbb.2022.173482_bb0155","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1037\/a0029087","article-title":"Alcohol increases impulsivity and abuse liability in heavy drinking women","volume":"20","author":"Reed","year":"2012","journal-title":"Exp. Clin. Psychopharmacol."},{"key":"10.1016\/j.pbb.2022.173482_bb0160","article-title":"The American Psychiatric Association practice guideline for the pharmacological treatment of patients with alcohol use disorder","volume":"5","author":"Reus","year":"2018","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.pbb.2022.173482_bb0165","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1097\/00002508-199603000-00010","article-title":"Gabapentin adjunctive therapy in neuropathic pain states","volume":"12","author":"Rosner","year":"1996","journal-title":"Clin. J. Pain"},{"key":"10.1016\/j.pbb.2022.173482_bb0170","first-page":"9","article-title":"Pretreatment with hydromorphone, a mu-opioid agonist, does not alter the acute behavioral and physiological effects of ethanol in humans","volume":"25","author":"Rush","year":"2001","journal-title":"Alcohol. Clin. Exp. Res."},{"key":"10.1016\/j.pbb.2022.173482_bb0175","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1097\/JCP.0b013e31822bb378","article-title":"Importance of gabapentin dose in treatment of opioid withdrawal","volume":"31","author":"Salehi","year":"2011","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.pbb.2022.173482_bb0180","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1037\/a0033724","article-title":"Randomized, placebo-controlled pilot trial of gabapentin during an outpatient, buprenorphine-assisted detoxification procedure","volume":"21","author":"Sanders","year":"2013","journal-title":"Exp. Clin. Psychopharmacol."},{"key":"10.1016\/j.pbb.2022.173482_bb0185","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.coph.2005.11.003","article-title":"The mechanisms of action of gabapentin and pregabalin","volume":"6","author":"Sills","year":"2006","journal-title":"Curr. Opin. PharmacolNeurosciences"},{"key":"10.1016\/j.pbb.2022.173482_bb0190","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1111\/add.13324","article-title":"Gabapentin misuse, abuse and diversion: a systematic review: gabapentin misuse and diversion review","volume":"111","author":"Smith","year":"2016","journal-title":"Addiction"},{"key":"10.1016\/j.pbb.2022.173482_bb0195","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1159\/000363232","article-title":"Alcohol use disorders in opioid maintenance therapy: prevalence, clinical correlates and treatment","volume":"21","author":"Soyka","year":"2015","journal-title":"Eur. Addict. Res."},{"key":"10.1016\/j.pbb.2022.173482_bb0200","first-page":"1353","article-title":"Assessment of alcohol withdrawal: the revised Clinical Institute Withdrawal Assessment for alcohol scale (CIWA-ar)","volume":"84","author":"Sullivan","year":"1989","journal-title":"Addiction"},{"key":"10.1016\/j.pbb.2022.173482_bb0205","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1080\/10826084.2019.1594904","article-title":"Alcohol use disorder and motives for prescription opioid misuse: a latent class analysis","volume":"54","author":"Votaw","year":"2019","journal-title":"Subst. Use Misuse"},{"key":"10.1016\/j.pbb.2022.173482_bb1010","doi-asserted-by":"crossref","DOI":"10.1002\/cpt1974164653","article-title":"Rating the presence and severity of opiate dependence","author":"Wang","year":"1974","journal-title":"Clin. Pharmacol. Ther."},{"issue":"3","key":"10.1016\/j.pbb.2022.173482_bb1020","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.drugalcdep.2008.05.007","article-title":"The relative abuse liability of oral oxycodone, hydrocodone and hydromorphone assessed in prescription opioid abusers","volume":"98","author":"Walsh","year":"2008","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.pbb.2022.173482_bb0210","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1093\/ajcn\/33.1.27","article-title":"Total body water volumes for adult males and females estimated from simple anthropometric measurements","volume":"33","author":"Watson","year":"1980","journal-title":"Am. J. Clin. Nutr."},{"key":"10.1016\/j.pbb.2022.173482_bb0215","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1016\/S0028-3908(97)00118-4","article-title":"The novel anticonvulsant, gabapentin, protects against both convulsant and anxiogenic aspects of the ethanol withdrawal syndrome","volume":"36","author":"Watson","year":"1997","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.pbb.2022.173482_bb0220","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1080\/02791072.2003.10400007","article-title":"The Clinical Opiate Withdrawal Scale (COWS)","volume":"35","author":"Wesson","year":"2003","journal-title":"J. Psychoactive Drugs"},{"key":"10.1016\/j.pbb.2022.173482_bb0225","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1016\/j.amjmed.2006.02.005","article-title":"Artificially sweetened versus regular mixers increase gastric emptying and alcohol absorption","volume":"119","author":"Wu","year":"2006","journal-title":"Am. J. Med."},{"key":"10.1016\/j.pbb.2022.173482_bb0230","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1007\/s00213-011-2349-6","article-title":"Subjective, psychomotor, and physiological effects of oxycodone alone and in combination with ethanol in healthy volunteers","volume":"218","author":"Zacny","year":"2011","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.pbb.2022.173482_bb0235","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1016\/j.pbb.2011.10.023","article-title":"Subjective, psychomotor, and physiological effects of pregabalin alone and in combination with oxycodone in healthy volunteers","volume":"100","author":"Zacny","year":"2012","journal-title":"Pharmacol. Biochem. Behav."},{"issue":"6","key":"10.1016\/j.pbb.2022.173482_bb1005","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/0376-8716(78)90014-5","article-title":"The quantitative assessment of physical dependence on opiates","volume":"3","author":"Zilm","year":"1978","journal-title":"Drug Alcohol Depend."}],"container-title":["Pharmacology Biochemistry and Behavior"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091305722001617?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091305722001617?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T04:43:57Z","timestamp":1758775437000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0091305722001617"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":52,"alternative-id":["S0091305722001617"],"URL":"https:\/\/doi.org\/10.1016\/j.pbb.2022.173482","relation":{},"ISSN":["0091-3057"],"issn-type":[{"value":"0091-3057","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Gabapentin increases the abuse liability of alcohol alone and in combination with oxycodone in participants with co-occurring opioid and alcohol use disorder","name":"articletitle","label":"Article Title"},{"value":"Pharmacology Biochemistry and Behavior","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pbb.2022.173482","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"173482"}}